Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | ADCY5 | O95622 | 6/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554851 | 1.00 | NR1I2 (0.56) | NR1I2ALBPDE4DADCY5ABCB1 | |
| SCHEMBL23587713 | 1.00 | NR1I2 (0.56) | NR1I2ALBPDE4DADCY5ABCB1 | |
| Hydrochloric Acid SCHEMBL9287359 | 0.99 | NR1I2 (0.55) | NR1I2ALBPDE4DADCY5ABCB1 | |
| Carbovir SCHEMBL8447674 | 0.86 | NR1I2 (0.56) | NR1I2ALBPDE4DADCY5BCHE | |
| Carbovir SCHEMBL3778804 | 0.86 | NR1I2 (0.56) | NR1I2ALBPDE4DADCY5BCHE | |
| Carbovir SCHEMBL19237554 | 0.86 | NR1I2 (0.56) | NR1I2ALBPDE4DADCY5BCHE | |
| Carbovir SCHEMBL180360 | 0.86 | NR1I2 (0.56) | NR1I2ALBPDE4DADCY5BCHE | |
| Carbovir SCHEMBL9867194 | 0.86 | NR1I2 (0.56) | NR1I2ALBPDE4DADCY5BCHE | |
| Abacavir SCHEMBL7795337 | 0.81 | NR1I2 (0.54) | NR1I2ALBPDE4DADCY5ABCB1 | |
| SCHEMBL7590599 | 0.78 | PDE4D (0.70) | NR1I2ALBPDE4DADCY5ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021133742-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-1235833-B1 | ANALOGS OF (1S, CIS)-4-(2-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030040506-A1 | Analogs of (1s,cis)-4-(2-amino-9h-purin -9-yl) -2-Cyclopentene-1-methanol as antiviral | SMITHKLINE BEECHAM CORPORATION | 2003-02-27 | — | — | US | disclosed |
| EP-0349242-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-03-22 | — | — | EP | disclosed |
| EP-0479822-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-15 | — | — | EP | disclosed |
| US-5049671-A | Hepatitis, AIDS | BURROUGHS WELLCOME CO. (US) | 1991-09-17 | — | — | US | disclosed |
| WO-1991000282-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-10 | — | — | WO | disclosed |
| EP-0349242-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040506-A1 | Analogs of (1s,cis)-4-(2-amino-9h-purin -9-yl) -2-Cyclopentene-1-methanol as antiviral | MAVS, ZC3HAV1, HAVCR2 | NR1I2 1441/4885ALB 3153/4885PDE4D 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.